Short Interest in Gamida Cell Ltd (NASDAQ:GMDA) Rises By 41.3%

Gamida Cell Ltd (NASDAQ:GMDA) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 47,200 shares, an increase of 41.3% from the September 30th total of 33,400 shares. Based on an average trading volume of 26,200 shares, the short-interest ratio is currently 1.8 days. Approximately 0.4% of the shares of the company are short sold.

Several equities analysts have commented on the company. Zacks Investment Research cut Gamida Cell from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th. Oppenheimer set a $18.00 price target on Gamida Cell and gave the company a “buy” rating in a report on Wednesday, August 7th. ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, JMP Securities assumed coverage on Gamida Cell in a report on Friday, September 20th. They issued an “outperform” rating and a $16.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.43.

Shares of GMDA traded up $0.09 during mid-day trading on Monday, reaching $4.96. The company had a trading volume of 3,227 shares, compared to its average volume of 24,279. Gamida Cell has a twelve month low of $2.93 and a twelve month high of $15.41. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.47 and a quick ratio of 4.47. The company’s 50-day moving average is $4.63 and its 200-day moving average is $5.29. The company has a market capitalization of $120.14 million and a P/E ratio of -0.47.

Institutional investors and hedge funds have recently modified their holdings of the company. Rock Springs Capital Management LP acquired a new position in shares of Gamida Cell in the 2nd quarter worth approximately $5,080,000. Noked Capital LTD acquired a new position in shares of Gamida Cell in the 2nd quarter worth approximately $1,035,000. Bank Hapoalim BM acquired a new position in shares of Gamida Cell in the 2nd quarter worth approximately $195,000. EcoR1 Capital LLC acquired a new position in shares of Gamida Cell in the 2nd quarter worth approximately $265,000. Finally, Royal Bank of Canada acquired a new position in shares of Gamida Cell in the 2nd quarter worth approximately $71,000. 25.86% of the stock is owned by institutional investors and hedge funds.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Further Reading: How to start trading in the forex market?

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.